Helicobacter pylori

helicobacter-pylori

Antigen Background

Helicobacter pylori is a motile, helix-shaped Gram-negative, microaerophilic, bacterial pathogen which is capable of converting from a spiral form to a coccoid form to favor its survival. Almost 50 percent of the world's population, approaching 100 percent in some countries, are infected. There are numerous strains of Helicobacter pylori which can be grouped into two broad families, type I and type II, based on their expression of the hopQ allele. Type I and type II strains are reported to express VacA (vacuolating toxin) responsible for vacuolation of gastric epithelial cells and induction of apoptosis. Type I strains are reported to express CagA protein which is associated with deregulation of intercellular signalling pathways and initiation of pathogenesis (virulent strains) and are closely related to gastric diseases such as peptic ulceration, gastric ulceration, chronic gastritis, mucosaassociated lymphoid tissue (MALT) lymphoma and intestine type gastric adenocarcinomas. Type II strains are reported not to express CagA proteins. HopE is a 31 kD porin protein which is part of a family of 32 outer membrane proteins present in Helicobacter pylori bacteria. HopE is highly conserved in Helicobacter pylori strains, but not among other strains of the Helicobacter genus.

Product Specific Information

Clone ULC3R, unlike polyclonal antibodies to Helicobacter pylori, does not cross-react with Campylobacter jejuni (a gastric bacterium which causes infective diarrhoea). Clone ULC3R also exhibits more defined staining of H. pylori bacteria than NCL-HPp. The antibody clone ULC3R, will be useful to identify and differentiate patients that need antibiotic eradication of the bacterium from those patients who are at a higher risk of developing clinical disease related to H. pylori infection.

  • IHC5994-A
    IHC5994 - 7ml HPp ASR
    POLYCLONAL
    Liquid ASR
    NA
  • HPYLORI-L-A
    1ml NCL-L-Hpylori ASR
    ULC3R
    Liquid Concentrate
    NA

Product Specifications

Product Specifications

IHC5994-A
Gastrointestinal Pathology
POLYCLONAL
Liquid ASR
No
NA
Poly
Rabbit
Analyte Specific Reagent
7ml
HPYLORI-L-A
Gastrointestinal Pathology
ULC3R
Liquid Concentrate
Yes
NA
Mono
Mouse
Analyte Specific Reagent
1ml

Documents

Documents

IHC5994-A
HPYLORI-L-A

Resources

Resources

Antigen Background

Helicobacter pylori is a motile, helix-shaped Gram-negative, microaerophilic, bacterial pathogen which is capable of converting from a spiral form to a coccoid form to favor its survival. Almost 50 percent of the world's population, approaching 100 percent in some countries, are infected. There are numerous strains of Helicobacter pylori which can be grouped into two broad families, type I and type II, based on their expression of the hopQ allele. Type I and type II strains are reported to express VacA (vacuolating toxin) responsible for vacuolation of gastric epithelial cells and induction of apoptosis. Type I strains are reported to express CagA protein which is associated with deregulation of intercellular signalling pathways and initiation of pathogenesis (virulent strains) and are closely related to gastric diseases such as peptic ulceration, gastric ulceration, chronic gastritis, mucosaassociated lymphoid tissue (MALT) lymphoma and intestine type gastric adenocarcinomas. Type II strains are reported not to express CagA proteins. HopE is a 31 kD porin protein which is part of a family of 32 outer membrane proteins present in Helicobacter pylori bacteria. HopE is highly conserved in Helicobacter pylori strains, but not among other strains of the Helicobacter genus.

Product Specific Information

Clone ULC3R, unlike polyclonal antibodies to Helicobacter pylori, does not cross-react with Campylobacter jejuni (a gastric bacterium which causes infective diarrhoea). Clone ULC3R also exhibits more defined staining of H. pylori bacteria than NCL-HPp. The antibody clone ULC3R, will be useful to identify and differentiate patients that need antibiotic eradication of the bacterium from those patients who are at a higher risk of developing clinical disease related to H. pylori infection.

Recently Viewed

View All